Q2 2025 Nektar Therapeutics Earnings Call Transcript

Aug 7, 2025 / 09:00 PM GMT

Release Date Price: MXN414

Transcript 10-Q8-K

Key Points

Positve

Nektar Therapeutics (NKTR) reported compelling initial data for ResPEG in ectopic dermatitis, establishing it as a potential first-in-class treatment.
The company received FDA fast track designation for both ectopic dermatitis and alopecia areata, allowing for expedited regulatory pathways.
Nektar Therapeutics (NKTR) completed a $115 million equity financing, strengthening its financial position and extending its cash runway into 2027.
The company plans to present additional data from the ongoing Resolve AD study, which could further characterize the durability and depth of response for ResPEG.
Nektar Therapeutics (NKTR) is actively engaging with potential partners for collaborations on ResPEG, exploring both strategic and non-dilutive financial methods.

Negative

The company faces uncertainties and risks related to forward-looking statements, which may result in actual outcomes differing materially.
Nektar Therapeutics (NKTR) reported a net loss of $41.6 million for the second quarter, highlighting ongoing financial challenges.
The company is involved in litigation with Lilly, which could impact its financial and operational resources.
There are concerns about injection site reactions (ISRs) associated with ResPEG, although efforts are being made to mitigate these effects.
The competitive landscape for treatments in ectopic dermatitis and alopecia areata is challenging, with existing therapies having established market presence.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NKTR.OQ - Nektar Therapeutics
Q2 2025 Nektar Therapeutics Earnings Call
Aug 07, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and thank you for standing by. Welcome to the Nectar Therapeutics. 2nd quarter 2025 Financial results conference call.

At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Corinne Franklin from Nectar Therapeutics Investor Relations to kick things off. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you and good afternoon, everyone.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.